Samuel Moskowitz, MD
Family Medicine · Edenton, NCNPI 1932336161
Payments from drug & device makers
Across 286 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$704
- Boehringer Ingelheim$444
- Johnson & Johnson$397
- Pfizer$324
- Amgen$294
- Lilly USA, LLC$277
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,508100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $704 |
| Boehringer Ingelheim | 26 | $444 |
| Johnson & Johnson | 40 | $397 |
| Pfizer | 19 | $324 |
| Amgen | 19 | $294 |
| Lilly USA, LLC | 17 | $277 |
| Novartis | 18 | $265 |
| AbbVie | 12 | $224 |
| Corcept Therapeutics | 10 | $211 |
| Abbott | 11 | $205 |
| Merck | 13 | $204 |
| AstraZeneca | 8 | $129 |
| Sanofi-aventis U.S. LLC | 7 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $100 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $61 |
| Mylan Specialty L.p. | 3 | $50 |
| Endo USA, Inc. | 2 | $50 |
| Astellas Pharma US Inc | 4 | $48 |
| Phathom Pharmaceuticals, Inc. | 4 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $37 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| GSK | 2 | $24 |
| Eisai Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Smith+Nephew | 1 | $19 |
| Grifols USA, LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $17 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Adlon Therapeutics L.p. | 1 | $11 |
How this compares
$4,508 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 117 | $109,240 |
| OzempicSemaglutide | 89 | $105,128 |
| JardianceEmpagliflozin | 100 | $103,908 |
| EliquisApixaban | 104 | $76,861 |
| RybelsusSemaglutide | 34 | $71,477 |
| XareltoRivaroxaban | 68 | $70,061 |
| MyrbetriqMirabegron | 40 | $23,844 |
| TrulicityDulaglutide | 15 | $23,430 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,379 |
| MounjaroTirzepatide | 15 | $16,042 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $13,256 |
| Nurtec OdtRimegepant Sulfate | 14 | $12,873 |
| Bydureon BciseExenatide Microspheres | 14 | $12,062 |
| Spiriva HandihalerTiotropium Bromide | 14 | $11,506 |
| TradjentaLinagliptin | 17 | $11,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $704 | $176,605123 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat | $444 | $128,915140 claims |
| MerckJanuvia | $204 | $109,240117 claims |
| PfizerEliquis, Nurtec Odt | $324 | $89,734118 claims |
| Johnson & JohnsonXarelto | $397 | $70,06168 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $277 | $42,39045 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $23,84440 claims |
| GSKTrelegy Ellipta | $24 | $21,37933 claims |
| AbbVieLinzess, Synthroid | $224 | $13,49459 claims |
| AstraZenecaSymbicort | $129 | $13,25648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Edenton
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.